NeuroPhage Pharmaceuticals Secures $6,400,000 New Funding Round

  • Feed Type
  • Date
    5/6/2013
  • Company Name
    NeuroPhage Pharmaceuticals
  • Mailing Address
    222 3rd St. Cambridge, MA 02142
  • Company Description
    NeuroPhage is developing a breakthrough protein dissaggregation platform for treatment of neurodegenerative diseases. Our lead Alzheimer’s disease (AD) drug candidate, NPT001, safely and effectively dissaggregates existing Aß plaque in preclinical animal models, which is unique among disease-modifying approaches for AD.
  • Website
    http://www.neurophage.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $6,400,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The new funds will help support ongoing pre-IND studies for lead compound NPT002 and will advance the development of second-generation fusion proteins with the potential for treating several neurodegenerative conditions including Alzheimer’s, Parkinson’s and Huntington’s diseases.
  • M&A Terms
  • Venture Investor
    bioMerieux
  • Venture Investor
    Shire Strategic Investment Group
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.